Detection of anti-MAGE-3.A1 CTLp. (A) Clinical evolution of patient CP64. (B) Detection of anti-MAGE-3.A1 CTL in postimmunization PBMC. PBMC were thawed, incubated with peptide MAGE-3.A1, washed, and distributed at 3.106 cells/well in the presence of IL-2, -4, and -7. On day 7, the cultures were restimulated with peptide and cytokines. On days 7 and 13, the cells were incubated with the A1/MAGE-3 tetramer coupled to PE and with a control HLA-A1 tetramer containing an influenza peptide and coupled to APC. Anti-CD3 antibodies coupled to FITC and anti-CD8 antibodies coupled to peridinin chlorophyll protein were then added. Cells were washed, fixed, and analyzed by flow cytometry. One million events were acquired, but the plots include only the CD3+CD8+ lymphocytes. The lytic activity of CTL clones, derived from two populations of cells labeled with tetramer, was tested on HLA-A1 EBV-B cells incubated or not with the MAGE-3.A1 peptide (2 μM), natural killer target cells K562, and allogenic melanoma cells MZ2-MEL, which naturally express the MAGE-3.A1 antigen. The pattern of lysis of two representative clones is shown. (C) Estimation of the frequency of anti-MAGE-3.A1 CTLp in postimmunization PBMC. Thirty-six cultures were set up with 160,000 Post II PBMC stimulated with the MAGE-3.A1 peptide and IL-2, -4, and -7. The lymphocytes were restimulated on day 7 by the addition of peptide and cytokines and labeled on day 15 with tetramers and anti-CD3 and anti-CD8 antibodies. Only CD3+CD8+ lymphocytes are included in the plots. Clusters of lymphocytes specifically labeled with the A1/MAGE-3 tetramer are boxed, and their proportion among the CD3+CD8+ cells is indicated. (D) Analysis of prevaccination PBMC. Five cultures of 3 million PBMC were set up and analyzed as in C.